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Objective: To examine the optimal cut-off values of visceral fat area (VFA) for predicting 
metabolic syndrome (MetS) among type 2 diabetes (T2D) patients in Ningbo China.
Methods: A total of 1017 subjects were selected from T2D patients who accepted standar-
dized management by the National Standardized Metabolic Disease Management Center at 
Ningbo First Hospital from March 2018 to January 2020. Demography and medical informa-
tion were collected through questionnaires. Regional adiposity was examined by a visceral 
fat analyzer using the dual bioelectrical impedance method.
Results: Overall, 769 (75.6%) T2D patients were defined to have MetS. Patients with MetS 
had higher anthropometric values and biomarkers, compared to those without MetS. VFA 
was significantly correlated with risk factors of MetS. Further logistic regression models 
showed that VFA was significantly associated with MetS in men (OR=1.02) and in women 
(OR=1.03) (P<0.001 for both genders) after controlling for related factors. Receiver- 
operating characteristic curve analysis demonstrated that the optimal cut-off values of VFA 
were 84.7 cm2 for men and 81.1 cm2 for women to predict MetS in T2D patients.
Conclusion: VFA was associated with MetS and could be an independent predictor of MetS 
in T2D patients.
Clinical Trial Registration: www.ClinicalTrials.gov, number: NCT03811470.
Keywords: abdominal obesity, metabolic syndrome, visceral fat area, type 2 diabetes
Introduction
Metabolic syndrome (MetS) is a cluster of conditions that contribute to the risk of 
cardiovascular diseases (CVD), heart disease, stroke and type 2 diabetes (T2D), 
which may increase all-cause mortality.1,2 MetS involves at least three out of five 
metabolic conditions, including hypertension, glucose intolerance, abdominal obe-
sity, decreased high-density lipoprotein cholesterol (HDL-C), and increased trigly-
ceride (TG) levels.3,4 The prevalence of T2D and MetS has increased rapidly in 
China due to rapid economic development and urbanization. The prevalence of 
MetS in adults was 10.5% in 2009 and 14.4% in 2014 in China5,6 based on the 
Chinese Diabetes Society (2004) criteria.7
Abdominal obesity, evaluated by waist circumference (WC), is known to be 
a critical contributor to cardio-metabolic risk factors,8,9 but WC is not able to 
distinguish visceral fat from subcutaneous adipose tissues effectively.10 Instead, 
abdominal visceral fat has been considered to be a more associative cardiovascular 
risk factor of body fat distribution than BMI and WC.11–13 Previous studies showed 
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that visceral fat area (VFA) was superior to BMI and WC 
to predict MetS and various cut-off values of VFA have 
been developed according to race, gender and age.14–17 
The accurate assessment and management of visceral fat 
accumulation were suggested to be critical to identify the 
cardiovascular risks among patients with T2D. Recently, 
computed tomography (CT), magnetic resonance imaging 
and dual-energy X-ray absorptiometry were recognized as 
the accurate methods to evaluate the visceral adipose 
tissue.18–20 However, due to the high cost of technology 
and high radiation exposure, these methods have been 
limited in clinical practice and have not been appropriate 
for screening purpose for a large population yet. In con-
trast, the dual current pathways bioelectrical impedance 
analysis (BIA) method was reported to measure central 
abdominal fat without X-ray exposure, with an accuracy 
for estimated VFA which was similar to the detection 
results of the X-ray CT method.20,21 Because of its sim-
plicity, noninvasiveness and relatively low cost, abdominal 
BIA can be used as a potentially good alternative measure 
of visceral fat accumulation.
With aging, fat mass tends to accumulate in the abdo-
men, and the risk of chronic diseases such as diabetes and 
CVD have been dramatically increased.22,23 Previous stu-
dies have shown that the prevalence of MetS was higher in 
people with T2D,24,25 and the cardiovascular mortality rate 
of subjects with metabolic syndrome was significantly 
increased regardless of the presence of T2D.24–27 Our 
previous research showed that the prevalence of MetS 
among adults in Ningbo was about 31%, which has 
reached a similar prevalence level of MetS in adults 
worldwide (20–30%).28 Therefore, establishment of an 
abdominal obesity assessment measure to accurately iden-
tify the risk of MetS and better control the risk of CVD in 
T2D is needed.
Up to date, few studies have examined the relationship 
between visceral fat and MetS in Chinese population. In 
addition, no study has explored the relationship between 
visceral fat and MetS in Chinese T2D patients. To fill in 
these research gaps, this study aimed to estimate optimal 
cut-off values of VFA and to investigate the risk of MetS 
among T2D patients in Chinese population.
Patients and Methods
Subjects
The present cross-sectional study recruited 1017 patients, 
diagnosed with T2D, aged from 18 to 75 years from 
March 2018 to January 2020 at the outpatient department 
of the Endocrinology of Ningbo First Hospital, Zhejiang 
province, China and the National Standardized Metabolic 
Disease Management Center (MMC). In order to meet all 
the challenges of metabolic diseases, the MMC program was 
launched in 2016.29 In MMC, patients can enjoy one-stop 
care, from registration, testing, evaluation, prescription to 
health education, and a series of comprehensive services to 
achieve a more convenient and accurate patient care model. 
T2D was diagnosed based on the definition proposed by the 
World Health Organization.30 We defined diabetes as fasting 
plasma glucose (FPG) ≥7.0 mmol/L (126 mg/dl) or 2h oral 
glucose tolerance test (OGTT) glucose ≥11.1 mmol/L 
(200 mg/dl). Subjects taking anti-diabetic drugs were also 
considered to have diabetes. The patients were excluded if 
they met any of the following criteria 1) age >75 years and 
age <18 years; 2) diagnosis with any kind of cancer; 3) 
positive islet autoantibodies; 4) glomerular filtration rate 
(eGFR) <30 mL/min; 5) severe liver dysfunction; 6) acute 
infectious diseases; 7) pregnancy or lactation.
The research project was approved by the Ethics 
Committee of Ningbo First Hospital, China (Ethics 
Approval No. 2019-R057) and followed the Declaration 
of Helsinki. Written informed consents were obtained 
from all participants.
Definition of Metabolic Syndrome
MetS was defined based on the 2017 Chinese Diabetes 
Society’s (CDS) criteria.31 The diagnostic criteria of MetS 
is the presence of three or more of the medical components: 
1) abdominal obesity: WC >90 cm in men or >85 cm in 
women; 2) hyperglycemia: FPG ≥ 6.1 mmol/L (110 mg/dl) or 
2-hour postprandial plasma glucose (2hPG) level ≥7.8 
(140 mg/dl) mmol/L or previously diagnosed with T2D; 3) 
hypertension: systolic blood pressure (SBP)/diastolic blood 
pressure (DBP) ≥130/85mmHg or previously diagnosed with 
hypertension and receiving medical treatments; 4) TG ≥ 1.7 
mmol/L (150 mg/dl); 5) HDL-C < 1.0 mmol/L (40 mg/dl). 
Since all subjects were diagnosed with T2D, MetS is defined 
at least two of the above medical components with the 
exception for 2). Based on the criteria of MetS, all subjects 
were divided into two groups: MetS (–) (T2D patients with 
no MetS) and MetS (+) (T2D patients defined as MetS).
Demographic and Clinical Characteristics
All patients were invited to complete the MMC standard 
questionnaires on their demography, lifestyle [smoking status 
(currently no smoking and currently smoking)], medical 
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history and medication records. Anthropometric measure-
ments included body weight and height were measured with-
out shoes and in light clothing by well-trained endocrinology 
nurses. Body weight was measured using an electronic scale 
to the nearest 0.1kg and height was measured using a metal 
column height meter to the nearest 0.1cm. WC was measured 
at the midpoint between the inferior costal margin and the 
iliac crest in the midaxillary line. Hip circumference was 
measured at the widest point over the buttocks, and the 
waist–hip ratio (WHR) was calculated as the ratio of waist 
to hip circumferences. BMI, used as a measure of general 
obesity, was calculated as weight (kg)/height (m2). Blood 
pressure was measured using an electronic sphygmoman-
ometer on the right or left arm after a 10-minute rest and 
the average of blood pressure was obtained on two 
assessments.
Biomarker Measurements
After a 10–12h-overnight fasting, blood samples were 
obtained in the early morning to measure the levels of 
blood profiles including FPG, fasting c-peptide (FCP), 
fasting insulin (FINS), glycated hemoglobin A1c 
(HbA1c), total cholesterol (TC), TG, HDL-C, low- 
density lipoprotein cholesterol (LDL-C), uric acid (UA) 
and serum creatinine (Scr). Then, the 100g flour (steamed 
bread meal) test was performed in all subjects to assess the 
2hPG, 2-hour postprandial C-peptide (2hCP) and 2-hour 
postprandial insulin (2hINS) concentrations.
FPG and 2hPG were assayed by the glucose oxidase 
method, FCP and 2hCP were determined by chemilu-
minescence immunoassay. Lipid profiles were analyzed 
by enzymatic procedures using an autoanalyzer 
(Hitachi 747; Hitachi, Tokyo, Japan). HbA1c was 
determined by high-pressure liquid chromatography. 
UA was examined by enzymatic spectrophotometry. 
Homeostasis model assessment-insulin resistance 
(HOMA-IR) was calculated as fasting serum insulin 
(mIU/L) × FPG (mmol/L)/22.5.32 HOMA-IR was used 
for further evaluation of insulin sensitivity. The eGFR 
was calculated following the formula: eGFR (mL/min/ 
1.73 m2) = 175 × Scr (mg/dl) −1.234 × age −0.179 × (1 
for men; 0.79 for women).33
Measurement of Visceral Fat Area and 
Subcutaneous Fat Area
VFA and subcutaneous fat area (SFA) of all participants with 
a 10- to 12-h fasting were measured by well-trained nurses. 
The measurements of body site for VFA and SFA were 
measured at the level of umbilicus with a visceral fat analy-
zer (DUALSCAN HDS-2000, Omron Healthcare Kyoto, 
Japan) using the abdominal dual BIA method.19,20 The 
resultant values were based on the impedance indicated by 
the difference in electrical conductivity between fat and non- 
fat tissue. Two paths were used to measure the impedance. 
The first path (A) applied low-voltage alternating current to 
a total of four electrodes fixed on both sides of the hands and 
feet. The system detected a constant micro-current value and 
calculated the bio-impedance value generated when passing 
through the limbs, thus calculating the non-fat area. 
The second path (B) applied a weak electric current between 
the electrodes placed on the abdomen and also measured the 
impedance. SFA of the abdomen can be calculated according 
to the abdominal impedance. The cross-sectional area of the 
abdomen at the umbilical level was calculated by the 
“abdominal detection unit” in advance. Afterwards, VFA 
was calculated following the formula: cross-sectional area 
- the sum areas of A and B.20
Measurement of Common Carotid 
Intima-Media Thickness
The intimal thickness of the carotid artery was measured with 
high-resolution B-mode ultrasound by experienced ultrasound 
experts. Patients were asked to take a supine position with 
their heads turning to the opposite side to fully expose the 
carotid artery. The intima-media thickness (IMT) on the distal 
wall of the common carotid artery on both sides was measured 
at about 1 cm from the carotid bifurcation. The greater value 
of the IMT of carotid artery from both sides was recorded as 
MaxIMT for analysis. Local carotid artery IMT greater than 
1.5 mm was defined as carotid plaque formation.34
Statistical Analysis
Continuous variables with normal and skewed distribu-
tions were presented as mean and standard deviation 
(SD), and median (interquartile range). Continuous vari-
ables were analyzed by Student’s t-test and Mann– 
Whitney U-test. Groups of categorical variables were com-
pared by χ2 test. Spearman correlation was conducted to 
examine the relationship between VFA and MetS factors. 
Logistic regression was used to examine the association 
between VFA (continuous variables; independent variable) 
and MetS (categorical variable; dependent variable). 
Associations were investigated after adjusting for related 
factors (age, currently smoking, HOMA-IR, UA and 
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currently using any kind of hypoglycemic medicines that 
might affect visceral fat accumulation [glucagon-like pep-
tide-1 (GLP-1) agonists, thiazolidinediones (TZDs), gli-
nides and sodium-dependent glucose transporters 2 
(SGLT-2) inhibitors]).35–38 Receive operating characteris-
tic (ROC) curve analysis was used to determine the diag-
nostic value of VFA for MetS in patients with T2D. The 
optimal cut-off values were obtained from the Youden 
index [maximum (sensitivity + specificity − 1)].39 
Results were considered statistically significant at a two- 
tailed level of 0.05. Statistical analyses were performed 
with IBM SPSS Statistics version 20.0.
Results
Clinical Characteristics of Study 
Individuals
A total of 1017 T2D patients (63.7% men) with a mean 
age of 54 years were finally included in the current study 
(Table 1). Around 75.6% (n=769) patients were defined as 
to have MetS (MetS +). Mean values of age, BMI, BP, 
VFA, SFA, WHR, FPG, FINS, 2hINS, HOMA-IR, FCP, 
2hCP, UA, TC, TG, LDL-C and maxIMT were signifi-
cantly higher in patients with MetS compared to those 
without MetS. Regarding glucose-lowering medicines, 
only currently using any kind of hypoglycemic medicines 
that affect VFA was taken was significantly more in the 
group of patients with MetS (P=0.013).
Relationship of Visceral Fat Area with the 
Risk Factors of Metabolic Syndrome
Spearman correlation was performed to examine the rela-
tionship of VFA with metabolic parameters stratified by 
sex (Table 2). Age was only significantly associated with 
VFA in women (r=0.134, P=0.012). VFA was positively 
correlated with all other parameters of anthropometry and 
biomarkers except for the negative correlation with HDL- 
C in women, and the Spearman correlation coefficients of 
VFA with BMI, SFA HOMA-IR and uric acid were 0.729, 
0.687, 0.343 and 0.390, respectively, while five parameters 
of MetS including FPG, 2hPG, HbA1c, TC and LDL-C 
were not associated with VFA in men.
The associations of MetS with VFA were further inves-
tigated by logistic regression (Table 3). VFA was asso-
ciated with 1.02 (CI 1.02–1.03) and 1.03 (CI 1.02–1.05) 
higher odds of developing MetS in both men and women, 
respectively, after controlling for potential risk factors. 
However, only age was associated with higher odds of 
MetS only in women (OR=1.05, CI 1.02–1.08, P<0.001) 
and uric acid was associated with higher odds of MetS 
only in men (OR=1.00, CI 1.00–1.01, P=0.034).
The Optimal Cut-Off Values of Visceral 
Fat Area for the Metabolic Syndrome
From the ROC curve analysis, the areas under the curve of 
ROC values of VFA predicting MetS were 0.752 (95% CI 
0.706–0.799, P<0.001) in men and 0.785 (95% CI 0.735–-
0.836, P<0.001) in women (Figure 1). The optimal cut-off 
value of VFA was 84.7 cm2 (sensitivity: 74.7%, specifi-
city: 65.8%) for men and 81.1 cm2 (sensitivity: 59.2%, 
specificity: 88.0%) for women (Table 4).
Discussion
In this study of a large clinical MMC study, the results of 
the current study showed that 75.6% T2D patients in 
Ningbo, China, were defined to have MetS. VFA and 
BMI were significantly associated with higher odds of 
MetS in both men and women. The optimal cut-off values 
of VFA predicting MetS among T2D patients was 84.7cm2 
in men and 81.1cm2 in women.
To date, no study has been conducted on VFA cut-off 
values among Chinese T2D patients. The prevalence of 
MetS in our study is relatively higher than those from 
previous reports.40–42 A recent study involving 15,492 
adult patients newly diagnosed with T2D in 46 tertiary 
care hospitals nationwide in China from 2015 to 2017 
reported that the prevalence of MetS was 68.1% using 
the 2017 CDS definition.31,40 The higher prevalence of 
MetS in our study can be explained that majority of our 
regional patients are not newly diagnosed T2D patients. 
Likewise, the prevalence of MetS in our study is relatively 
higher than the same patients in Ethiopia (66.7%)41 and in 
Korea (men: 46.9%; women: 65.1%) both using the US 
National Cholesterol Education Program Adult Treatment 
Panel III (NCEP ATP III) criteria.3,42
The guidelines from the CDS (2004) adapted BMI 
≥25 kg/m2 to define abdominal obesity predicting MetS 
among Chinese population.7 Additionally, International 
Diabetes Federation proposed a global diagnosis definition 
of MetS in 2005 and suggested the differential cut-off 
values of WC for defining abdominal obesity that reflected 
different races in each country.10 However, the body fat 
distribution of the Chinese population is characterized by 
abdominal fat accumulation. Evidence showed that Asians 
were more inclined to have obesity-related consequences 
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Table 1 Baseline Clinical Characteristics of Patients with Type 2 Diabetes
Total N=1017 MetS (-) N=248 MetS (+) N=769 P value
Male, n (%) 648 (63.7) 151 (60.9) 497 (64.6) 0.287
Age (years) 54 (47–61) 53 (45–59) 55 (47–62) 0.022
Currently smoking, n (%) 254 (24.9) 66 (26.6) 188 (24.4) 0.493
Anthropometry and biomarkers
SBP (mmHg) 132.95 ± 18.06 125.05 ± 15.23 135.49 ± 18.17 <0.001
DBP (mmHg) 78.56 ± 11.02 75.05 ± 10.16 79.7.0 ± 11.04 <0.001
Weight (kg) 69.23 ± 12.82 62.07 ± 10.92 71.54 ± 12.54 <0.001
BMI (kg/m2) 25.23 ± 3.64 22.86 ± 2.84 26.00 ± 3.52 <0.001
Waist circumference (cm) 89.03 ± 9.94 81.62 ± 8.70 91.42 ± 9.11 <0.001
Hip circumference (cm) 95.06 ± 7.19 91.23 ± 6.60 96.29 ± 6.93 <0.001
WHR 0.94 ± 0.07 0.90 ± 0.10 0.94 ± 0.06 <0.001
VFA (cm2) 93.82 ± 40.06 68.58 ± 34.65 101.98 ± 38.28 <0.001
SFA (cm2) 179.41 ± 62.88 142.79 ± 49.11 191.23 ± 62.32 <0.001
FPG (mmol/L) 8.57 ± 2.94 8.21 ± 3.07 8.69 ± 2.89 0.027
2hPG (mmol/L) 13.63 ± 4.97 13.54 ±5.51 13.66 ± 4.77 0.742
FINS (mIU/L) 11.30 (6.26–30.17) 7.42 (4.30–18.90) 12.30 (7.43–34.88) <0.001
2hINS (mIU/L) 38.52 (21.44–92.32) 28.45 (15.42–66.45) 43.23 (22.97–104.5) <0.001
HbA1c (%) 7.70 (6.50–9.20) 7.40 (6.40–9.20) 7.80 (6.60–9.20) 0.146
HOMA-IR 4.11 (2.19–11.49) 2.62 (1.44–6.97) 4.84 (2.60–13.15) <0.001
FCP (μg/L) 1.73 (1.00–2.53) 1.32 (0.73–1.87) 1.92 (1.11–2.73) <0.001
2hCP (μg/L) 4.08 (2.42–6.04) 3.41 (1.96–4.92) 4.26 (2.63–6.35) <0.001
Uric acid (mmol/L) 333.86 ± 85.01 303.36 ± 80.06 343.70 ± 84.26 <0.001
Total cholesterol (mmol/L) 4.52 ± 1.24 4.17 ± 1.08 4.63 ± 1.26 <0.001
Triglycerides (mmol/L) 1.43 (1.00–2.14) 1.05 (0.79–1.37) 1.70 (1.12–2.36) <0.001
HDL-C (mmol/L) 1.16 ± 0.29 1.16 ± 0.35 1.15 ± 0.28 0.829
LDL-C (mmol/L) 4.52 ± 1.24 2.68 ± 0.80 2.93 ± 0.89 <0.001
Max IMT (mm) 0.80 (0.60–1.00) 0.80 (0.60–0.90) 0.80 (0.60–1.00) 0.032
Carotid plaque, n (%) 365 (35.9) 70 (28.2) 295 (38.4) 0.006
Duration of diabetes (years) 6.58 (2.50–12.00) 6.50 (2.10–12.06) 6.6 (2.75–12.00) 0.363
Glucose-lowering medication treatments, n (%)
Insulin 338 (33.2) 89 (35.9) 249 (32.4) 0.346
TZDs 25 (2.5) 5 (2.0) 20 (2.6) 0.605
Sulfonylureas 326 (32.1) 88 (35.5) 238 (30.9) 0.210
Glinides 107 (10.5) 23 (9.3) 84 (10.9) 0.537
GLP-1 agonists 135 (13.1) 33 (12.8) 102 (13.3) 0.930
Biguanides 683 (67.2) 166 (66.9) 517 (67.2) 0.993
Alpha-GIs 367 (36.1) 85 (34.3) 282 (36.7) 0.544
DPP4 inhibitors 287 (28.2) 69 (27.8) 218 (28.3) 0.937
SGLT-2 inhibitors 80 (7.9) 21 (8.5) 59 (7.7) 0.788
Currently using any kind of hypoglycemic medicines that affect 
VFA‡
681 (70.9) 54 (22.6) 280 (31.1) 0.013
Notes: Data represent mean standard deviation or median (interquartile range 25–75%). ‡Currently using any kind of hypoglycemic medicines that affect visceral fat 
accumulation included GLP-1 agonists, TZDs, glinides and SGLT-2 inhibitors. 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WHR, waist–hip ratio; VFA, visceral fat area; SFA, subcutaneous fat area; 
FPG, fasting plasma glucose; 2hPG, 2-hour postprandial plasma glucose; FINS, fasting plasma insulin, 2hINS, 2-hour postprandial plasma insulin; HbA1c, glycated hemoglobin 
A1c; HOMA-IR, homeostasis model assessment for insulin resistance; FCP, fasting c-peptide; 2hCP, 2-hour postprandial c-peptide; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol; max IMT, max common carotid intima-media thickness. TZD, thiazolidinedione; GLP-1 agonists, glucagon-like 
peptide-1 agonists; alpha-GIs, alpha-glucosidase inhibitor; DPP4 inhibitors, dipeptidyl peptidase-4 inhibitors; SGLT-2 inhibitors, sodium-dependent glucose transporters 2 
inhibitors.
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at a lower BMI or a lower WC because of higher body fat 
mass deposition, compared to Caucasians.43,44 Around 
14% abdominal fat mass deposition was reported in 
Chinese, although their BMI was lower than cut-off 
value of 25 kg/m2.45 VFA is suggested to be a more 
accurate measurement than both WC and BMI for defining 
abdominal obesity.14–17 Comparable results have been 
reported in China on healthy Chinese population, VFA 
≥80 cm2 was proposed as an optimal cut-off value for 
predicting MetS and WC of 90 cm for men and 85 cm 
for women proposed as the cut-off values for the diagnosis 
of abdominal obesity in China.16 A 7.8-year follow-up 
study, conducted on healthy adults, indicated that abdom-
inal obesity in an independent risk factor causing T2D and 
VFA ≥90 cm2 was proposed as the cut-off values to define 
Table 2 Spearman Correlation Between VFA and Metabolic 
Parameters
VFA (cm2)
Men (n=648) Women (n=369)
r P value r P value
Age (years) 0.042 0.291 0.134 0.012
SBP (mmHg) 0.309 <0.001 0.246 <0.001
DBP (mmHg) 0.215 <0.001 0.157 0.003
BMI (kg/m2) 0.659 <0.001 0.729 <0.001
SFA (cm2) 0.665 <0.001 0.687 <0.001
FPG (mmol/L) 0.049 0.224 0.177 <0.001
2hPG (mmol/L) 0.021 0.607 0.116 <0.001
FINS (mIU/L) 0.337 <0.001 0.328 <0.001
2hINS (mIU/L) 0.267 <0.001 0.216 <0.001
HbA1c (%) −0.016 0.692 0.211 <0.001
HOMA-IR 0.325 <0.001 0.343 <0.001
FCP (μg/L) 0.310 <0.001 0.286 <0.001
2hCP (μg/L) 0.206 <0.001 0.148 0.006
Uric acid (mmol/L) 0.235 <0.001 0.390 <0.001
Total cholesterol 
(mmol/L)
0.032 0.420 0.045 <0.001
Triglycerides (mmol/L) 0.337 <0.001 0.384 <0.001
HDL-C (mmol/L) −0.215 <0.001 −0.241 <0.001
LDL-C (mmol/L) 0.012 0.765 0.116 0.029
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, 
body mass index; VFA, visceral fat area; SFA, subcutaneous fat area; FPG, fasting 
plasma glucose; 2hPG, 2-hour postprandial plasma glucose; FINS, fasting plasma 
insulin, 2hINS, 2-hour postprandial insulin; HbA1c, glycated hemoglobin A1c; FCP, 
fasting c-peptide; 2hCP, 2-hour postprandial c-peptide; HDL-C, high-density lipo-
protein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Table 3 Logistic Regression Analysis of Associated with MetS§ in 
Patients with Type 2 Diabetes
Men (n=648) Women (n=369)
Odds Ratio 
(95% CI)
P value Odds Ratio 
(95% CI)
P value
Age (year) 1.01 (0.99–1.03) 0.400 1.05 (1.02–1.08) <0.001
VFA (cm2) 1.02 (1.02–1.03) <0.001 1.03 (1.02–1.05) <0.001
Uric acid 
(mmol/L)
1.00 (1.00–1.01) 0.034 1.00 (0.99–1.01) 0.094
HOMA-IR 1.00 (0.99–1.01) 0.618 1.02 (0.99–1.04) 0.138
Currently 
smoking§
1.33 (0.85–2.09) 0.210 0.52 (0.24–1.12) 0.092
Currently using 




0.88 (0.55–1.40) 0.577 1.56 (0.84–2.87) 0.156
Notes: §MetS (-), currently no smoking and currently no hypoglycemic medicines 
treatment [human glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), 
glinides and sodium-dependent glucose transporters 2 (SGLT-2) inhibitors] are references 
in the models. 
Abbreviations: CI, confidence interval; VFA, visceral fat area; HOMA-IR, home-
ostasis model assessment for insulin resistance.
Figure 1 ROC curves for cut-off value of VFA to predict MetS. In men: area under the 
curve=0.752, 95% CI 0.706–0.799, P<0.001. Sensitivity and specificity at a VFA of 84.7 cm2 
were 74.7% and 65.8%, respectively. In women: area under the curve=0.785, 95% CI 
0.735–0.836, P<0.001. Sensitivity and specificity at a VFA of 81.1 cm2 were 59.2% and 
88.0%, respectively.
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abdominal obesity.46 In addition, VFA cut-off value of 
100 cm2 was proposed for Japanese adults to define 
abdominal obesity indicating the risk of obesity-related 
diseases with NCEP-ATP III definition.3,15 Kim et al 
reported that the optimal VFA using NCEP-ATP III defini-
tion associated with an increased risk of obesity-related 
diseases was 103.8 cm2 in Korean adults in both 
genders.3,17 Our VFA cut-off values were much lower 
than the results from Japanese and Korean studies. It 
might be caused by the various definitions of MetS.
Considering the gender-specific cut-off values for VFA 
in our study, VFA was significantly correlated with risk 
factors of T2D, especially in women. Logistic regression 
model, as expected, illustrated VFA indicated 
a significantly increased risk of MetS in patients with 
T2D. Previous studies suggested that the VFA cutoff 
value was associated with MetS.16,17 The mechanisms 
between VFA, and MetS and various components are 
complex and unclear yet. The possible mechanisms 
might be that visceral fat can secrete various hormones 
and inflammatory cytokines, such as tumor necrosis factor- 
a and interleukin-6, which can affect the insulin sensitivity 
of peripheral tissues.47,48 With a higher rate of lipolysis of 
visceral fat than subcutaneous fat, decomposed products of 
VFA, such as free fatty acids and glycerin, directly enter 
the liver through the portal vein circulation, stimulating 
liver lipoprotein synthesis and gluconeogenesis, reducing 
liver insulin removal, and increasing blood glucose and 
insulin resistance.49,50 Thus, excessive visceral fat accu-
mulation is more likely to induce diabetes, MetS and 
CVD. Our results also confirmed that insulin resistance 
and abdominal obesity were important features of MetS in 
diabetes. Moreover, age was found to be associated with 
high odds of MetS in women in our study. Recent studies 
indicated that age is a key factor playing a role in devel-
oping MetS.51,52 No cut-off value of VFA has been stan-
dardized among Chinese T2D patients yet. Lee et al52 and 
his colleagues reported that cut-off values increased with 
age, particularly among women, which in line with our 
finding. Due to post-menopause, women tend to be 
sensitive to accumulate fat mass in waist area.53 With no 
stratification of age, it might explain the lower sensitivity 
in our study.
The present study has some limitations. First, causality 
between VFA and MetS cannot be inferred according to 
the nature of cross-sectional study design. Second, VFA 
results might be affected by gender, age, medication, and 
the shape of the human body or the distribution of water in 
the patients’ body. Then, due to different lifestyles and 
regional patients from Ningbo, China, thus, the findings 
cannot be generalized to the general Chinese population. 
The last but not least, considering the small sample size, 
subgroup of age could not be analyzed.
Conclusions
The present study is the first study reporting the gender- 
specific optimal cut-off values of VFA for T2D patients in 
Ningbo, China, and predicted the optimal cut-off values of 
VFA be 84.7 cm2 in men and 81.1 cm2 in women. Our results 
demonstrated that MetS was common in T2D patients. VFA 
was a strong risk factor for the development of the MetS 
among T2D patients. Therefore, T2D patients with a VFA 
over the optimal cut-off values should be closely monitored 
for the development of MetS, and further prospective studies 
are needed to validate the relationship between the suggested 
VFA cut points and MetS in people with T2D.
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